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Objective. Antipsychotics have been associated with increased cardiac events includingmortality.This study assessed cardiac events
including mortality among antipsychotic users relative to nonusers. Methods. The General Practice Research Database (GPRD)
was used to identify antipsychotic users, matched general population controls, and psychiatric diseased nonusers. Outcomes
included cardiac mortality, sudden cardiac death (SCD), all-cause mortality (excluding suicide), coronary heart disease (CHD),
and ventricular arrhythmias (VA). Sensitivity analyses were conducted for age, dose, duration, antipsychotic type, and psychiatric
disease. Results. 183,392 antipsychotic users (115,491 typical and 67,901 atypical), 544,726 general population controls, and 193,920
psychiatric nonusers were identified. Nonusers with schizophrenia, dementia, or bipolar disorder had increased risks of all-cause
mortality compared to general population controls, while nonusers with major depression had comparable risks. Relative to
psychiatric nonusers, the adjusted relative ratios (aRR) of all-cause mortality in antipsychotic users was 1.75 (95% CI: 1.64–1.87);
cardiac mortality 1.72 (95% CI: 1.42–2.07); SCD primary definition 5.76 (95% CI: 2.90–11.45); SCD secondary definition 2.15 (95%
CI: 1.64–2.81); CHD 1.16 (95% CI: 0.94–1.44); and VA 1.16 (95% CI: 1.02–1.31). aRRs of the various outcomes were lower for atypical
versus typical antipsychotics (all-cause mortality 0.83 (95% CI: 0.80–0.85); cardiac mortality 0.89 (95% CI: 0.82–0.97); and SCD
secondary definition 0.76 (95%CI: 0.55–1.04).Conclusions. Antipsychotic users had an increased risk of cardiac mortality, all-cause
mortality, and SCD compared to a psychiatric nonuser cohort.
1. Introduction
Antipsychotics used for the treatment of schizophrenia and
other mental illnesses have been associated with increased
mortality (including sudden cardiac death) and major car-
diac events. Several observational studies have assessed this
association [1–4]. A retrospective cohort study of Medicaid
enrollees in Tennessee found that for current users of both
typical and atypical antipsychotics the risk of sudden cardiac
death increased with increasing dose [4]. Among users of
atypical agents, the incidence-rate ratios increased from 1.59
(95% CI, 1.03–2.46) for those taking low doses to 2.86 (95%
CI, 2.25–3.65) for those taking high doses. Limitations of
the study included the inability to fully control for major
potential confounders (e.g., increasing disease severity with
increasing dose, untreated psychosis, unhealthy lifestyle,
current smoking, abuse of alcohol and other substances [4]),
and the validity of the definition of sudden cardiac death
(SCD).
Themechanism for the potential increased risk of sudden
cardiac death with the use of antipsychotics is not known.
A possible association between sudden cardiac death has
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been explained by a lengthening of ventricular repolarization
(QT interval prolongation) predisposing to life-threatening
ventricular tachyarrhythmias (i.e., torsades de pointes) [4].
However, it has been described that antipsychotics may have
a clear differential risk in prolonging the QT interval [5].
More than 80% of cases of sudden cardiac death occur in
individuals with coronary heart disease [6–8]. SCD occurs
in only 5% to 10% of subjects without a positive history
for coronary heart disease or congestive heart failure [9]
and the most common electrophysiological mechanisms
leading to SCD are ventricular tachyarrhythmias. Risk factors
for SCD include family history of coronary artery disease,
increased LDL cholesterol, hypertension, smoking, and dia-
betes mellitus [10–13]. Various reports suggest that patients
with schizophrenia have a significantly increased burden of
cardiovascular disease and diabetes than the general popu-
lation and that cardiovascular mortality contributes to the
excess mortality in persons with schizophrenia regardless of
their treatment [2, 14–16].This increased burden ofmetabolic
changes could increase the risk of SCD.
To further evaluate the findings of these studies, this
retrospective database study was performed to assess the pri-
mary the potential risk of cardiac mortality including sudden
cardiac death as the primary outcome and the following sec-
ondary outcomes—the risk of all-cause mortality (excluding
suicide) and ofmajor cardiac events (including acutemyocar-
dial infarction (AMI), CHD, and life-threatening ventricular
arrhythmias), in the antipsychotic exposed population. This
study attempted to adjust for additional known risk factors
for SCD not previously assessed in other studies, smoking
status, body mass index, and alcohol status, and to address
issues with the definition of sudden cardiac death. The study
was designed to evaluate the potential relationship between
antipsychotic drug use, psychiatric illness, cardiac mortality,
all-cause mortality (excluding suicide), and major cardiac
events.
2. Methods
2.1. Data Source. This study used data from the UK General
Practice Research Database (GPRD), now administered by
the Clinical Practice Research Datalink. GPRD is comprised
of anonymised computerised medical records from primary
care for about 8% of the UK population. GPs play a key role
in the UK health care system, as they are responsible for
primary health care and specialist referrals. Details on the
history of GPRD and validation studies have been published
[17, 18]. At the time of this study, about 40% of the practices
participated in the anonymous and patient-level linkage to
the national registry of hospital admission (Hospital Episode
Statistics [HES]) and death certificates (as collected by the
Office of National Statistics [ONS]). For each hospitalised
patient, their hospital charts are reviewed and their dates
of admission, discharge and main diagnoses are extracted,
coded by coding staff, and collated nationally into HES. The
death certificates list the date and causes of death. HES data
were available from April 1997 and death certificates from
January 2001. The data from HES, death certificates, and
Table 1: Antipsychotic drugs screened among the target population.
Antipsychotic medication Drug substance
Atypical
Amisulpride
Aripiprazole
Clozapine
Olanzapine
Paliperidone
Quetiapine
Risperidone
Sertindole
Zotepine
Typical
Perphenazine
Benperidol
Chlorpromazine
Chlorprothixene
Droperidol
Flupentixol
Fluphenazine
Haloperidol
Levomepromazine
Loxapine
Oxypertine
Pericyazine
Pimozide
Promazine
Remoxipride
Sulpiride
Thioridazine
Trifluoperazine
Trifluperidol
Zuclopenthixol
GPRD were recorded and collected independently from each
other.
2.2. Study Population
2.2.1. Antipsychotic Users. A flow chart of the population
of antipsychotic users (exposed cohort) eligible for study is
shown in Figure 1. Antipsychotic medications screened in
this study are listed in Table 1 and were identified on the
basis of the corresponding Multilex codes for the respective
therapy. Patients were classified at the index date (first date of
antipsychotic prescribing in the study period) into prevalent
and incident antipsychotic users: incident users as those
with a first-ever prescription; prevalent users as those who
received an antipsychotic prescription prior to index date.
Each user of antipsychotics was matched to three general
population controls on age, gender, general practice, and
calendar time.
2.2.2. General Population Controls. General population con-
trols had no recorded use of antipsychotics (no recorded
Multilex code for screened antipsychotics (Table 1)) or no
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All permanently registered in
the GPRD between
N = 10,949,239
Patients with at least one
antipsychotic oral formulation
N = 314,822
Patients with at least one year
after GPRD data collection
Patients with at least 12months
of preindex followup
N = 187,245
Eligible population of
antipsychotic users
N = 183,392
Patients 18 years and over with
first prescription
on or after 01/01/1995
N = 187,390
3853: excluded
3,195: life threatening
tachyarrhythmia
180: history of congenital conduction
disorder or advanced cardiomyopathy
12: implantation of cardiac
defibrillation
466: cardioversion or aborted cardiac
arrest
N = 204,916
(01/01/1995 and 31/01/2011)
Figure 1: Flow diagram showing the composition of the study population, oral antipsychotic users.
history of psychiatric disorders (no documentation of a Read
coded diagnosis for schizophrenia, bipolar disorder/other
mood disorders, major depression, or dementia in the patient
clinical or referral record). The index date was at least 12
months after the start of GPRD data collection for each
patient.
2.2.3. Psychiatric Nonusers. A cohort of patients with a
diagnosis of schizophrenia, bipolar disorder/other mood
disorders, major depression, or dementia but without a
history of use of antipsychotics was also identified (referred
to as psychiatric nonusers). The index date was defined as
the date of the first record of the psychiatric disorder (i.e.,
both incident and prevalent cases were included).
Psychiatric non-users who were subsequently prescribed
antipsychotics after the index date of their psychiatric dis-
order were censored at the date of their first antipsychotic
prescription.Thus, person time for psychiatric nonusers con-
sisted of follow-up between their first psychiatric diagnosis
date and the end of follow-up (for patients with no record
of antipsychotic treatment) or prior to their antipsychotic
censor date for those who were treated. The duration of
psychiatric disease was calculated as the difference between
the earliest of the antipsychotic censor date, patient’s transfer
out date, or practice last collection date, and the date of first
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psychiatric disorder recorded during the GPRD followup.
This cohort was not matched to the cohort of antipsychotic
users; rather baseline differences were adjusted for using
multivariate analysis.
2.2.4. Exclusions. Patients with a Read coded medical diag-
nosis of a congenital conduction disorder or advanced
cardiomyopathy (hypertrophic or dilated) at any time in
the patient record were excluded. Patients with a Read
coded medical diagnosis of life-threatening ventricular
tachyarrhythmia, cardioversion, aborted cardiac arrest, or
implantation of a cardiac defibrillator prior to or on their
registration date were also excluded. Additionally, after
matching (where applicable), patients with a life-threatening
ventricular tachyarrhythmia, cardioversion, aborted cardiac
arrest, or implantation of a cardiac defibrillator prior to or on
the index date were excluded.
Patients were followed from the index date up to the
occurrence of the outcome of interest or the end of data
collection (i.e., last GPRD data collection and transfer out of
the practice or date of death, whichever date came first).
2.3. Antipsychotic Treatment
2.3.1. Treatment Exposure. For antipsychotic users, treatment
exposure was classified into three periods: (i) “current expo-
sure” is the period from issuing an antipsychotic prescription
up to 1 month after the expected end of treatment. Patients
who were issued repeat prescription within a month (30.4
days) after the expected end of a prescriptionwere assumed to
be continuously treated (ii) recent exposure is the period from
1 month after the expected end of use of a treatment until 6
months after, and (iii) past exposure is any subsequent follow-
up time after recent treatment (until censoring or a further
prescription). In some analyses current treatment was also
examined according to cumulative duration of treatment or
the strength of treatment at any given time period. Followup
among users was restricted to the “current exposure” period.
The defined daily dose (DDD) for prescriptions was
calculated based on the prescribed daily dose and strength
per tablet. These DDDs were then converted to the chlorpro-
mazine equivalents of low, medium, or high dose using the
dose thresholds for antipsychotics defined in chlorpromazine
equivalents [20]. Given the BritishNational Formulary (BNF)
recommendation that DDDs should be between 25 and
1000mg, converted DDDs outside of this range were treated
as unknown values. All unknown DDD values were imputed
using the median value of the distribution of all calculable
DDDs for the respective antipsychotic therapy and where
this was unavailable, using the median value for individual
drug types.The overall proportion of unknownDDD records
which were imputed was 9%. Estimated DDDs converted
to chlorpromazine equivalents per day were classified as
low daily dose [<200mg], medium [200–399mg], and high
[≥400mg].
2.3.2. Treatment Duration. The estimated duration of use of
therapywas calculated as the prescription quantity divided by
daily dose. Where the estimated duration was missing or was
estimated as <1 or >91.4 days (corresponding approximately
to the 1st and 99th percentiles of the distribution of all
estimated prescription durations), the estimated durations
were imputed using the median for that prescription, or
where this was unavailable, using the median pertaining to
the subtype of that substance instead. The overall proportion
of estimated duration records, across all prescriptions, which
were imputed, was 13%. The tertiles of the distribution of
cumulative treatment duration at the end of followup for all
exposed patients were calculated.These cutoffs corresponded
broadly to (a) <1 year, (b) 1–3 years, or (c) >3 years and
were used to further categorise current treatment for analyses
investigating cumulative treatment duration.
2.4. Outcomes of Interest
2.4.1. Primary and Secondary Outcomes. The outcomes of
interest included cardiac mortality, three definitions for
sudden cardiac death (SCD), all-cause mortality excluding
suicide (referred to as all-cause mortality from here on
out), coronary heart disease (CHD), and life-threatening
ventricular arrhythmias. Outcomes were identified using
GPRD Read codes, ICD10 codes from ONS death certificates
data, and records fromHES (Table 2). In addition, GPRD free
text information was used to improve the odds of accurately
identifying SCD cases.
2.4.2. Free Text Search Methodology. The average number of
characters of free text per patient was estimated for each
practice in GPRD stratified by calendar time. Based on the
changes in average amount of free text over calendar time, a
starting year of 2006was selected for use of free text. Practices
were then ranked by the average amount of free text overall.
The Free text review for primary and secondary SCD cases
was restricted to the 243 practices with an above median
amount of free text per patient in each practice and restricted
to followup after 2006. The free texts in the 3 weeks around
a death date were searched for string terms suggestive of
sudden cardiac death (Table 2). Anonymised text before and
after each instance that a text string appeared was selected,
to a maximum of 500 characters (including spaces) before
and 500 characters after the string. Free text results were
then independently reviewed by two internal clinical experts
from Lilly (a third expert was used in case of discordant
assessment) and relevant events were included.
2.4.3. Case Ascertainment Using GPRD Read Codes, Free Text,
and Death Certificate Data. When queryingmultiple sources
for the occurrence of an outcome, the following hierarchy
was used, with earlier-named sources taking precedence over
the later-named sources when more than one was available
for any given patient: death certificate (both the recorded
date and cause of death), followed by GPRD free text (date
of death taken to be the minimum of the recorded GPRD
date of death or free text date), followed by GPRD Read code
(date of death taken to be the minimum of the recorded
GPRD date of death or the date of Read code). Where both
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Table 2: Definitions for outcomes of interest.
All-cause mortality Deaths due to any cause except suicide.
Cardiac mortality Based on death certificates with ICD 10 codes I10, I11.9, I20, I21, I22, I23, I24, I25, I42.8, I42.9,I46, I47, I49.0, I49.8, I49.9, I51.6, I51.9, I70.9, R09.2, R96, R98
SCD primary definition
This was a narrow definition of SCD and the most restrictive. The SCD diagnosis was derived
from the following ICD10 codes recorded on death certificates (available for January 1998 to
November 2010): I46, I47.2, I49.0, R09.2, R96 [19], from Read codes in GPRD that correspond
to these ICD10 codes, or from free text in the ±3 weeks before or after the death recording.
Data from a national registry of hospital admission (Hospital Episode Statistics [HES],
available for April 1997 to October 2010) were used to ensure that the event took place outside
the hospital. A mortality event that occurred within 30 days after the hospital discharge date
was not included in the SCD definition.
SCD secondary definition
This definition is broader than the primary definition and is similar to the definition used by
Ray et al. (2009) [4]. The SCD diagnosis was derived from death certificates with ICD 10 codes
I10, I11.9, I20, I21, I22, I23, I24, I25, I42.8, I42.9, I46, I47, I49.0, I49.8, I49.9, I51.6, I51.9, I70.9,
R09.2, R96.1, R98, from Read codes in GPRD that correspond to these ICD10 codes, or from
free text in the ±3 weeks before or after the death recording. Cases with a HES record of
hospitalisation were excluded.
SCD tertiary definition This definition was the same as the secondary definition with the exception that only data fromGPRD and not from death certificates or HES were used.
SCD (based on free text)
The following text strings were used to identify sudden cardiac death from GPRD free text:
“dropped dead,” “died unexpectedly,” “sudden cardiac death,” “death” and “cause unknown, ”
“acute cardiac death,” “unexpected” and “death,” “mors subita,” “death instanta, ” “died instanta,
” “sudden death,” “dropped dead,” and “died suddenly.”
CHD Based on GPRD Read codes; data from a national registry of hospital admission (HospitalEpisode Statistics (HES) ICD10 codes I21 or I22; or cardiac procedures)
Life-threatening
Ventricular arrhythmias Based on GPRD Read codes or HES ICD10 I49.0.
a Read code and a free text term were recorded, the earlier
of the two events was considered as the date of the event.
For example, under our primary definition of sudden cardiac
death a patient was classified as a case on the basis of their
cause of death but not on their GPRD Read codes only.
However, if their caseness was based on GPRD Read codes
there was no need for supporting evidence in the free text
also. A conservative approach in identifying the SCD cases
was used, counting them as SCD cases unless the free text
clearly specified another cause of death.
2.5. Statistical Analyses. Poisson regression analysis was used
to examine the rates of each outcome and produce corre-
sponding age and sex-adjusted (RRs) and fully adjusted rela-
tive ratios (aRRs) and 95% confidence intervals (CI) for each
comparison. Adjusted models were fitted using automated
backward elimination with stepwise regression. To ensure
that the resulting models were not overparameterised, the
number of variables to be included in the model was selected
using the rule of thumb of five outcome events per parameter
[21, 22]. Goodness-of-fit was assessed by examining the
associated 𝑃 values of the covariates such that a covariate
was included in the model only if the associated 𝑃 value was
<0.05, while any covariates in the model with 𝑃 values ≥0.10
were excluded. The following patient characteristics were
considered as potential confounders in regression models:
age, sex, socioeconomic status (Index ofMultipleDeprivation
calculated at the postcode of the patient’s residence), smoking
history, alcohol use, and body mass index. Age, sex, and
treatment (atypical, typical, or current antipsychotic use,
depending on analysis) were included in the model a priori.
BMI was calculated using the most recent BMI measurement
available prior to index date. Nonsmokers were classified
as patients with a record of nonsmoking only, documented
in their record. Current smoking was based on the most
recent smoking record of the patient documented prior to the
index date. Regression models included indicator variables
for missing values for BMI and smoking. Other confounding
factors included were time since start of GPRD data col-
lection (in tertiles), duration of psychiatric disease, history
of cardiovascular disease, alcohol or drug abuse, diabetes
mellitus, history of suicide attempt, prior hospital admission
for psychiatric disease and prescribing in the 3 months
before of statins or fibrates, antihypertensive drugs, warfarin,
antiplatelets, nitrates, lithium, antiepileptics, antidepressants,
and anxiolytics. To examine changes in risk over time,
patient followup (from start of medication until end of data
collection) was subdivided into 100 periods of equal length
and incidence rates (hazard rates) estimated for each period.
These rates were smoothed using the methods proposed by
Ramlau-Hansen [23]. Analyses were conducted using STATA
11.
3. Results
The exposed cohort included 183,392 antipsychotic users
(Table 3). Patients had a mean age of 60.3 years (SD: 22.1)
and average duration of follow-up of 4.0 years (SD: 4.0).
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Table 3: Baseline characteristics at index date of the patients exposed to antipsychotics, psychiatric nonuser cohort, and general population
controls.
Characteristic
Exposed to
antipsychotics
(𝑁 = 183,392)
Typical
antipsychotics
(𝑁 = 115,491)
Atypical
antipsychotics
(𝑁 = 67,901)
Psychiatric
nonusers
(𝑁 = 193,920)
General
population control
(𝑁 = 544,726)
Prevalent users 67,396 (36.7%) 40,258 (34.9%) 27,138 (40.0%) 0 (0.0%) 0 (0.0%)
Female 107,226 (58.5%) 69,426 (60.1%) 37,800 (55.7%) 132,458 (68.3%) 317,152 (58.2%)
Male 76,166 (41.5%) 46,065 (39.9%) 30,101 (44.3%) 61,462 (31.7%) 227,574 (41.8%)
Age: mean (sd) 60 (22) 61 (21) 58 (23) 52 (22) 60 (22)
Age: median (IQR) 62 (41–80) 64 (44–80) 58 (38–81) 48 (33–75) 61 (41–80)
Age 18–29 18,474 (10.1%) 9,180 (7.9%) 9,294 (13.7%) 34,559 (17.8%) 55,188 (10.1%)
Age 30–39 23,484 (12.8%) 13,747 (11.9%) 9,737 (14.3%) 38,574 (19.9%) 70,462 (12.9%)
Age 40–49 23,793 (13.0%) 14,554 (12.6%) 9,239 (13.6%) 28,555 (14.7%) 71,370 (13.1%)
Age 50–59 21,244 (11.6%) 14,627 (12.7%) 6,617 (9.7%) 21,302 (11.0%) 63,724 (11.7%)
Age 60–69 19,923 (10.9%) 14,461 (12.5%) 5,462 (8.0%) 13,831 (7.1%) 59,723 (11.0%)
Age 70–79 28,088 (15.3%) 18,881 (16.3%) 9,207 (13.6%) 21,194 (10.9%) 84,519 (15.5%)
Age 80+ 48,386 (26.4%) 30,041 (26.0%) 18,345 (27.0%) 35,905 (18.5%) 139,740 (25.7%)
BMI: mean (sd) 26 (6) 26 (5) 26 (6) 26 (6) 26 (5)
Nonsmoker 69,482 (37.9%) 44,035 (38.1%) 25,447 (37.5%) 80,061 (41.3%) 249,362 (45.8%)
Ex-smoker 29,719 (16.2%) 17,638 (15.3%) 12,081 (17.8%) 39,550 (20.4%) 99,240 (18.2%)
Smoker 51,938 (28.3%) 31,361 (27.2%) 20,577 (30.3%) 57,004 (29.4%) 102,455 (18.8%)
Unknown smoking status 32,253 (17.6%) 22,457 (19.4%) 9,796 (14.4%) 17,305 (8.9%) 93,669 (17.2%)
Schizophrenia 15,475 (8.4%) 6,746 (5.8%) 8,729 (12.9%) 7,779 (4.0%) 0 (0.0%)
Bipolar disorder/other
mood disorders 7,368 (4.0%) 3,170 (2.7%) 4,198 (6.2%) 4,700 (2.4%) 0 (0.0%)
Major depression 19,981 (10.9%) 11,680 (10.1%) 8,301 (12.2%) 134,105 (69.2%) 0 (0.0%)
Dementia 25,174 (13.7%) 12,669 (11.0%) 12,505 (18.4%) 47,336 (24.4%) 0 (0.0%)
No recorded specific
psychiatric disorders 115,394 (62.9%) 81,226 (70.3%) 34,168 (50.3%) 0 (0.0%) 544,726 (100.0%)
History of alcoholism or
drug abuse 19,933 (10.9%) 11,429 (9.9%) 8,504 (12.5%) 12,572 (6.5%) 13,256 (2.4%)
History of suicide
attempts 10,777 (5.9%) 5,762 (5.0%) 5,015 (7.4%) 8,841 (4.6%) 3,537 (0.6%)
Diabetes mellitus 15,276 (8.3%) 9,480 (8.2%) 5,796 (8.5%) 13,639 (7.0%) 36,069 (6.6%)
Acute myocardial
infarction 6,530 (3.6%) 4,224 (3.7%) 2,306 (3.4%) 5,466 (2.8%) 19,391 (3.6%)
Prescribing of
statins/fibrates in the 3
months before
16,203 (8.8%) 8,406 (7.3%) 7,797 (11.5%) 18,124 (9.3%) 49,148 (9.0%)
Antiplatelets 32,260 (17.6%) 18,900 (16.4%) 13,360 (19.7%) 25,397 (13.1%) 72,622 (13.3%)
Antidepressants 83,595 (45.6%) 49,545 (42.9%) 34,050 (50.1%) 126,688 (65.3%) 34,393 (6.3%)
Anxiolytics 27,389 (14.9%) 15,637 (13.5%) 11,752 (17.3%) 12,907 (6.7%) 10,185 (1.9%)
Selective serotonin
reuptake inhibitors 44,428 (24.2%) 24,330 (21.1%) 20,098 (29.6%) 98,373 (50.7%) 16,263 (3.0%)
Lithium 5,122 (2.8%) 2,851 (2.5%) 2,271 (3.3%) 1,743 (0.9%) 115 (<0.1%)
Antiepileptics 10,090 (5.5%) 5,853 (5.1%) 4,237 (6.2%) 3,817 (2.0%) 5,855 (1.1%)
Typical antipsychotic users (115,491 (63.0%)) were slightly
older (mean age: 61.4 years (SD: 21.1)) compared to atypical
users (mean age: 58.3 years (SD: 23.3)) andwere followed for a
longer duration than atypical users (4.7 years (SD: 4.5) versus
2.9 years (SD: 2.7)). Typical antipsychotic users also had a
longer mean duration of psychiatric disease (6.8 years (SD:
9.8)) when compared to atypical users (5.8 years (SD: 8.8)).
Specific GPRD codes for the type of psychiatric disease were
not available in two-thirds of the exposed cohort due to lack
of specific psychiatric diagnosis documented in the patient’s
record. Patients in the exposed cohort were well matched to
general population controls on age, gender, general practice
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Table 4: Confounding by underlying psychiatric disease comparing rates of all-cause mortality (excluding suicide) or cardiac mortality in
the psychiatric nonuser cohort to that of the general population controls.
Outcome Psychiatric Disease No. ofcases
Incidence
rate per 1000
person-years
Age, sex-adjusted
relative risk (RR)
(95% CI)
Fully adjusted RR
(aRR) (95% CI)
Mortality
None (general population) 295 10.9 Reference Reference
Patients with bipolar
disorders 43 15.2 1.50 (1.09–2.07)
† 1.40 (1.01–1.95)†
None (general population) 19,858 96.5 Reference Reference
Dementia 4,445 142.8 1.54 (1.49–1.59)‡ 1.45 (1.40–1.50)‡
None (general population) 8,890 9.9 Reference Reference
Major depression 3,230 11.3 1.40 (1.35–1.46)‡ 1.05 (0.98–1.12)
None (general population) 513 10.1 Reference Reference
Schizophrenia 55 23.1 2.23 (1.69–2.94)‡ 1.99 (1.50–2.65)‡
Cardiac mortality
None (general population) 34 1.8 Reference Reference
Patients with bipolar
disorders 5 2.4 —(NC
#) —(NC#)
None (general population) 4257 28.9 Reference Reference
Dementia 795 32.2 1.16 (1.08–1.25)‡ 1.15 (1.06–1.24)‡
None (general population) 1363 2.4 Reference Reference
Major depression 484 2.7 1.39 (1.25–1.54)‡ 1.00 (0.85–1.17)
None (general population) 66 2.2 Reference Reference
Schizophrenia 8 5.5 2.04 (0.98–4.26)∗ —(NC#)
∗
𝑃 < 0.10, †𝑃 < 0.05, ‡𝑃 < 0.01, #Not calculable due to small number of cases.
and calendar time.Themean age and duration of follow-up of
general population controls was 60.0 years (SD: 21.8) and 4.8
years (SD: 4.0), respectively. The psychiatric nonuser cohort
comprised of 193,920 patients with amean duration of follow-
up of 4.1 years (SD: 3.5). Psychiatric nonusers were on average
younger (52.3 years (SD: 22.0)) and had a shorter duration
of psychiatric disease (0.9 years (SD: 4.1)) compared to the
exposed cohort.
The use of typical antipsychotics decreased over calendar
time, while that of atypical antipsychotics increased. The
mean cumulative duration of prescribing among patients
initiated on antipsychotics was 1.6 years (SD: 2.7). The mean
cumulative duration of prescribing of typical and atypical
antipsychotics during the study period was 1.2 years (SD: 2.4)
and 2.1 years (SD: 2.9), respectively, regardless of the type of
antipsychotic initiated at cohort entry.
Table 4 shows the results of the comparisons of the
psychiatric nonuser cohort and general population controls,
providing an analysis of the possible extent of confounding.
In the psychiatric nonuser cohort, compared to the general
population, age and sex-adjusted rates of all-cause mortality
were increased in patients with schizophrenia, dementia,
bipolar disorder, and major depression. This trend persisted
after adjustment for major risk factors of all-cause mortality
among conditions of interest except for major depression.
However, the possibility of confounding by unmeasured risk
factors such as disease severity cannot be excluded. There
were also trends for increased risks of cardiac mortality in
unexposed patients with major affective disorders compared
to the general population, although the number of cases was
smaller which did not allow for fully adjusted comparisons.
The rates of cardiac mortality, all-cause mortality, and
sudden cardiac death (regardless of the definition) were
increased in the exposed cohort compared to both the
general population controls and the psychiatric nonuser
cohort (Table 5). The risk of sudden cardiac death using the
primary definition was increased fourfold in antipsychotic
users (aRR of 4.03 (95% CI 2.63–6.16) compared to general
population controls).There were no significant differences in
the rate of CHD between the exposed cohort compared to
the general population controls and the psychiatric nonuser
cohort compared to their general population controls.
The rates of all-cause mortality, cardiac mortality, SCD
(using the tertiary definition), and CHD were significantly
lower with atypical antipsychotics compared to typical
antipsychotics, as shown in Table 6. The rate of sudden
cardiac death (using the secondary definition) was 24% lower
with atypical antipsychotics (aRR of 0.76 (95% CI 0.55–
1.04)). Figure 2 shows the crude ratios of smoothed hazard
ratios of all-causemortality in users of atypical antipsychotics
compared to those in users of typical antipsychotics by year
of treatment. The rate of all-cause mortality was lower with
atypical antipsychotics during the first year of treatment
while the rates were more comparable to those with typical
antipsychotics with longer use.
Table 7 shows the primary causes of death in users of
typical and atypical antipsychotics. The rate of death due to
neoplasmswas higher in users of typical antipsychotics, while
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Table 5: RR of all-cause mortality (excluding suicide) and cardiac mortality in exposed cohort, psychiatric nonuser cohort, and general
population controls.
Outcome Exposure No. of cases
Incidence
rate per 1000
person-years
Age, sex-adjusted
relative risk (RR)
(95% CI)
Fully adjusted RR
(aRR) (95% CI)
All-cause
mortality
General population 41,546 39.6 Reference Reference
Current use 23,841 86.1 2.98 (2.93–3.03)‡ 2.72 (2.67–2.77)‡
Psychiatric nonusers 7,765 25.3 Reference Reference
Current use 23,841 86.1 2.15 (2.10–2.21)‡ 1.75 (1.64–1.87)‡
Cardiac
mortality
General population 6,532 11.9 Reference Reference
Current use 2,478 17.0 2.01 (1.92–2.10)‡ 1.83 (1.74–1.93)‡
Psychiatric nonusers 1,289 6.4 Reference Reference
Current use 2,478 17.0 1.62 (1.52–1.74)‡ 1.72 (1.42–2.07)‡
SCD-primary
definition
General population 46 0.8 Reference Reference
Current use 44 2.7 4.45 (2.94–6.73)‡ 4.03 (2.63–6.16)‡
Psychiatric nonusers 10 0.4 Reference Reference
Current use 44 2.7 5.76 (2.90–11.45)‡ 5.76 (2.90–11.45)‡
SCD-secondary
definition
General population 244 4.0 Reference Reference
Current use 178 11.0 3.48 (2.87–4.23)‡ 2.89 (2.32–3.60)‡
Psychiatric nonusers 98 4.1 Reference Reference
Current use 178 11.0 2.36 (1.84–3.02)‡ 2.15 (1.64–2.81)‡
SCD-tertiary
definition
General population 370 2.3 Reference Reference
Current use 198 4.6 2.47 (2.08–2.94)‡ 2.11 (1.73–2.56)‡
Psychiatric nonusers 119 1.8 Reference Reference
Current use 198 4.6 1.92 (1.53–2.42)‡ 1.79 (1.42–2.27)‡
CHD
General population 5,993 6.6 Reference Reference
Current use 1,269 5.4 1.06 (1.00–1.13)∗ 0.94 (0.87–1.00)∗
Psychiatric nonusers 982 3.5 Reference Reference
Current use 1,355 5.7 1.08 (1.00–1.18)∗ 1.16 (0.94–1.44)
Ventricular
arrhythmias
General population 1,977 2.2 Reference Reference
Current use 646 2.7 1.53 (1.40–1.67)‡ 1.49 (1.35–1.64)‡
Psychiatric nonusers 500 1.8 Reference Reference
Current use 646 2.7 1.14 (1.01–1.28)† 1.16 (1.02–1.31)†
∗
𝑃 < 0.10, †𝑃 < 0.05, ‡𝑃 < 0.01.
death due to cardiovascular disease were similar to those
patients using atypical antipsychotics.
The aRRs of all-cause mortality and cardiac mortality
were found to vary by age (Table 8). The aRR of all-cause
mortality was 4.12 in antipsychotic users aged <30 years
and 1.43 in users aged ≥80 years. The incidence rates were
considerably higher in elderly users, indicating that the excess
absolute risks were largest in the elderly users. Increasing
risk with increasing dose was observed among antipsychotic
users for cardiac mortality, but not for all-cause mortality
compared to psychiatric nonuser controls.
4. Discussion
This study used data from a large primary care population
in the UK. We found that all-cause mortality and cardiac
mortality (including SCD) were significantly higher among
antipsychotic users versus controls.We also observed that the
risk of all-cause mortality and cardiac mortality was lower
when comparing current antipsychotic users to psychiatric
non-users than when comparing current user to the general
population. This finding suggests that the mortality risk for
current antipsychotic users and psychiatric non-users ismore
similar than to that of the general population, suggesting an
increased risk for severe psychiatric disorders irrespective
of management. When the risks of cardiac mortality, all-
cause mortality, and cardiovascular outcomes were assessed
according to the first type of antipsychotic prescribed to
users, the relatives rates of these outcomes were found to
be lower in patients exposed to atypical compared to typical
antipsychotics. An increased risk of all-cause mortality was
found in psychiatric non-userswith schizophrenia, dementia,
bipolar disorder, or major depression, when compared to
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Table 6: RR of all-cause mortality (excluding suicide) or cardiac mortality in users of atypical and typical antipsychotics.
Outcome Type ofantipsychotic No. of cases
Incidence rate per
1000 person-years
Age, sex-adjusted
relative risk (RR)
(95% CI)
Fully adjusted RR
(aRR) (95% CI)
All-cause mortality Typical 15,334 91.5 Reference Reference
Atypical 7,555 76.0 0.79 (0.77–0.81)‡ 0.83 (0.80–0.85)‡
Cardiac mortality Typical 1,130 17.8 Reference Reference
Atypical 1,214 16.1 0.84 (0.78–0.91)‡ 0.89 (0.82–0.97)‡
SCD primary
definition
Typical 20 3.8 Reference Reference
Atypical 22 2.1 —(NC#) —(NC#)
SCD secondary
definition
Typical 77 14.5 Reference Reference
Atypical 95 9.1 0.72 (0.53–0.97)† 0.76 (0.55–1.04)∗
SCD tertiary
definition
Typical 97 6.3 Reference Reference
Atypical 99 3.7 0.66 (0.50–0.87)‡ 0.70 (0.53–0.93)†
CHD Typical 867 6.3 Reference Reference
Atypical 459 5.1 0.80 (0.72–0.90)‡ 0.85 (0.76–0.96)‡
Ventricular
arrhythmias
Typical 382 2.8 Reference Reference
Atypical 242 2.7 0.94 (0.80–1.10) 0.93 (0.79–1.10)
∗
𝑃 < 0.10, †𝑃 < 0.05, ‡𝑃 < 0.01, #Not calculable due to small number of cases.
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Figure 2: Smoothed crude RR of all-cause mortality (excluding
suicide) and 95% Confidence Interval over treatment time in users
of atypical antipsychotics compared to matched users of typical
antipsychotics. x-axis: RR, y-axis: Time since start treatment (years).
the general population controls. Statistical adjustment for
baseline risk factors did not modify these results, except
with major depression. Confounding by indication is a major
challenge in this type of research. Patients diagnosed with
psychiatric disorders who experience severe symptoms may
bemore likely to be treatedwith certain types of antipsychotic
medication. Thus, if severity of disease is associated with the
outcome under study, findings from observational studies
may be a reflection of this unmeasured confounding rather
than a true drug-disease relationship.
Patients with mental illness may be at higher risk of
cardiovascular outcomes. The results of the mortality com-
parison between psychiatric nonuser patients and general
population controls support the presence of substantial
confounding in patients with psychiatric disease. Increased
risks of mortality have also been reported in a large Danish
study comparing patients admitted to a psychiatric hospital
to the general population [24]. In the present study, statistical
adjustment in regression analyses (beyond age and sex
adjustment) did not minimise this confounding (i.e., the
crude and adjusted effect estimates did not vary greatly),
with the exception of major depression. More sophisticated
techniques such as matching by propensity scores could be
used, but this technique also cannot address confounding
by unmeasured characteristics (such as clinical severity of
psychiatric disease). It would clearly be preferable to evaluate
the mortality risks of antipsychotics in a large randomised
trial. Unfortunately, trials evaluating antipsychotics use are
generally short in duration [25].
Although we found that the rates of CHD between the
exposed cohort compared to general population controls and
the diseased unexposed cohort were similar this observation
may be partly explained by the very narrow definition used
to identify CHD in the study—CHD was evaluated as a
record of acute myocardial infarction (ICD-10 codes I21and
I22) or cardiac procedures documented during the study
period. It is also plausible that precursors of CHD go undi-
agnosed/undetected in psychiatric patients due to complexity
of care and competing priorities in disease management.
The Food and Drug Administration has warned that the
use of antipsychotics poses an increased risk of death in
elderly patients with dementia-related psychosis. In a meta-
analysis by Schneider et al. of randomized placebo-controlled
parallel group clinical trials in patients with dementia,
authors found that death occurred more often in subjects
randomized to drug (3.5%) than to placebo (2.3%) [26]. We
found that the risks ofmortality and cardiovascular outcomes
were lower with atypical compared to typical antipsychotics.
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Table 7: Causes of death categorised according to ICD-10 chapter in current users of typical and atypical antipsychotics.
Class
Atypical Typical
Events (𝑁, %)
Incidence rate per
1000 person-years
(95% CI)
Events (𝑁, %)
Incidence rate per
1000 person-years
(95% CI)
A00-B99: certain infectious and
parasitic diseases 63 [0.9] 1.98 (1.52–2.53) 46 [0.5] 1.41 (1.03–1.89)
C00-D89: neoplasms/diseases of the
blood and blood forming organs
and certain disorders involving the
immune mechanism
585 [8.2] 1.68 (1.55–1.83) 3955 [43.1] 4.83 (4.68–4.98)
E00-E90: endocrine, nutritional,
and metabolic disorders 114 [1.6] 1.50 (1.24–1.80) 106 [1.2] 1.75 (1.43–2.12)
F00-F99: mental and behavioural
disorders 907 [12.7] 1.45 (1.36–1.55) 607 [6.6] 1.49 (1.37–1.61)
G00-G99: diseases of the nervous
system 657 [9.2] 1.37 (1.27–1.48) 384 [4.2] 1.41 (1.27–1.55)
I00-I99: diseases of the circulatory
system 2119 [29.6] 1.66 (1.59–1.73) 1755 [19.1] 1.72 (1.64–1.81)
I20-I25: ischemic heart disease 670 [9.4] 1.59 (1.48–1.72) 570 [6.2] 1.57 (1.44–1.70)
I50: heart failure 108 [1.5] 1.71 (1.40–2.07) 94 [1.0] 2.11 (1.70–2.58)
J00-J99: diseases of the respiratory
system 924 [12.9] 1.52 (1.42–1.62) 819 [8.9] 1.57 (1.46–1.68)
K00-K93: diseases of the digestive
system 212 [3.0] 1.33 (1.15–1.52) 191 [2.1] 1.40 (1.21–1.61)
L00-L99: diseases of the skin and
subcutaneous tissue 20 [0.3] 2.78 (1.70–4.30) 18 [0.2] 1.22 (0.72–1.93)
M00-M99: diseases of the
musculoskeletal system and
connective tissue
44 [0.6] 1.83 (1.33–2.45) 34 [0.4] 1.90 (1.32–2.66)
N00-N99: disease of the
genitourinary system 183 [2.6] 1.51 (1.30–1.74) 162 [1.8] 1.67 (1.42–1.94)
Q00-Q99: congenital
malformations, deformations, and
chromosomal abnormalities
8 [0.1] 2.04 (0.88–4.02) 8 [0.1] 2.13 (0.92–4.19)
R00-R99: symptoms, signs, and
abnormal clinical and laboratory
findings
264 [3.7] 1.58 (1.40–1.79) 265 [2.9] 2.08 (1.83–2.34)
V01-Y98: external causes of
morbidity and mortality 277 [3.9] 1.63 (1.44–1.83) 160 [1.7] 1.26 (1.07–1.47)
Differences in baseline characteristics generally appeared
smaller between users of typical and atypical antipsychotics.
Our findings of lower mortality risks with atypical antipsy-
chotics are consistent with other observational studies [27–
31], with the exception of a small study in the Netherlands
[32]. However, when the analysis was confined to users who
were prescribed antipsychotic medication within 6 months
of death the analysis of users of typical antipsychotics had
a higher rate of death due to neoplasms but similar rates
of death due to cardiovascular disease compared to users of
atypical antipsychotics.This observation is likely confounded
by disease duration and severity but may suggest that our
finding of a more favourable outcome during treatment with
atypical antipsychotics may be one that is apparent in the
early stages of disease, but that long term use of atypical
antipsychotics carries a similar risk of death to that of typical
antipsychotics users. Further study is warranted.
A recent study by Huybrechts et al. of 75,000 new
antipsychotic users found increased risks of death due to
cardiovascular, cerebrovascular and respiratory disease in
users of haloperidol compared to users of risperidone [30].
The results on death due to cancer were not presented and
it is unknown whether the differential risks of mortality
between typical and atypical antipsychotics also applied to
death due to cancer. The mechanisms through which typical
antipsychotics might increase the risk of death are unclear
[31].
We compared our results to those of previous observa-
tional studies, most notably Ray et al. [4]. Consistent with
Ray et al., when assessing SCD overall (using the secondary
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Table 8: Relative risk of all-cause mortality (excluding suicide), cardiac mortality, and sudden cardiac death in users of antipsychotics
compared to psychiatric nonuser controls stratified by age and daily dose.
Outcome Characteristic No. of cases Incidence rate per 1000person-years
Fully adjusted RR
(aRR) (95% CI)
All-cause mortality
Age < 30 121 4.5 4.12 (2.72–6.25)‡
Age 30–64 3,473 22.3 2.23 (1.85–2.68)‡
Age 65–79 6,563 127.6 1.78 (1.57–2.02)‡
Age ≥ 80 13,684 322.3 1.43 (1.31–1.55)‡
Cardiac mortality
Age < 30 7 0.4 —(NC#)
Age 30–64 219 2.8 2.39 (1.80–3.19)‡
Age 65–79 682 27.1 1.60 (1.40–1.83)‡
Age ≥ 80 1,570 63.0 1.55 (1.22–1.98)‡
SCD-primary
definition
Age < 30 1 0.5 —(NC#)
Age 30–64 8 1.0 —(NC#)
Age 65–79 12 4.5 —(NC#)
Age ≥ 80 23 7.4 —(NC#)
All-cause mortality
Low daily dose 21208 97.0 1.72 (1.62–1.84)‡
Medium daily dose 1978 52.5 1.94 (1.80–2.10)‡
High daily dose 655 31.9 1.89 (1.71–2.09)‡
Cardiac mortality
Low daily dose 2157 20.0 1.65 (1.36–2.00)‡
Medium daily dose 251 9.9 2.10 (1.68–2.63)‡
High daily dose 70 5.6 2.27 (1.68–3.07)‡
SCD-primary
definition
Low daily dose 39 3.3 5.87 (2.92–11.78)‡
Medium daily dose 4 1.4 5.51 (1.69–17.96)‡
High daily dose 1 0.8 3.81 (0.47–30.59)
∗
𝑃 < 0.10, †𝑃 < 0.05, ‡𝑃 < 0.01, #Not calculable due to small number of cases.
definition, which most closely corresponds to the Ray defi-
nition [4]), users of both typical and atypical antipsychotics
had an increased risk of SCD when compared to nonusers
with psychiatric illness. The risk of SCD increased with
increasing atypical antipsychotic dose, a finding which was
not borne out in the present study, although we did find
increasing risk with increased doses of typical antipsychotics
for the secondary SCD definition (results not shown). Our
analysis assessing the risk of all-cause mortality among
users of any antipsychotic relative to psychiatric nonusers
(1.75 (95% CI, 1.64–1.87)) is consistent with that reported
by Enger et al. (2.18 (95% CI, 1.14–4.18)) [2] in his study
comparing the risk of all-cause mortality (excluding suicide),
cardiovascular mortality, acute myocardial infarction (MI),
and arrhythmias in people with schizophrenia who were
prescribed antipsychotics. Reports by Osborn et al. [14] on a
previous study conducted in the GPRD on the risk of cardiac
and cancer mortality in people with severe mental illness
also corroborate our findings of an increased relative risk of
cardiac death among antipsychotic users.
We found some evidence of a direct dose-response
relationship between antipsychotic prescribing and cardiac
mortality. This relationship persisted even when antipsy-
chotic therapy was stratified by typical and atypical use
and individual antipsychotic therapy (results not shown). A
similar trend was reported by Bralet et al. [33] albeit among
male patients only, while Enger et al. [2] reported an inverse
relationship. Ray et al. [4] reported a direct relationship
between atypical antipsychotics and SCD, but our study was
not sufficiently powered to provide reliable estimates of this
effect. Using our primary definition of SCD we were only
able to identify a very small number of cases with SCD (4
cases were prescribed medium dose and 1 case at high dose).
This makes it difficult to draw any conclusions regarding a
potential dose-response relationship with SCD.
Our finding of excess mortality across all age groups
of psychiatric patients has been well described [34–37].
However, the decline in the aRR of all-cause and cardiac
mortality with increasing age is surprising. As patients with
psychiatric disease tend to have many risk factors for death,
some of which could not be accounted for in our analysis,
we expected to observe an increase in the relative risk of
mortality with age. The age related decline in mortality may
be explained by the healthy survivor effect [14, 38]; younger
patients with poorer health and more serious psychiatric
disease die earlier leaving the older and potentially healthier
patients in the study. Our findings of an inverse age mortality
trend are similar to that reported by Osborn et al. [14] who
showed that the hazard ratio for CHD mortality in patients
with severe mental illness relative to controls were 3.22 (95%
CI, 1.99–5.21); 1.86 (95% CI, 1.63–2.12); and 1.05 (95% CI,
0.92–1.19) for people aged 18–49, 50–75, and>75, respectively.
The risk of mortality among users of atypical medica-
tions relative to typical users increased over time and was
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higher after two years of use. This increase in mortality
may potentially be due to the longer-term outcomes in
patients who experience changes in metabolic parameters
during treatment with atypical antipsychotics [39] and to the
growing problem of antipsychotic polypharmacy [40]. These
metabolic factors could explain increasedmortality over time
and after two years of use; mortality secondary to potential
changes in QT interval prolongation is likely to occur at
earlier stages of treatment [5].
There are various strengths to this study. The present
study included a large number of patients and outcomes that
were obtained through three independently collected data
sources, including prospectively collected hospital admission
data and death certificates. Additionally, patient followup
occurred over a relatively long period. Despite the study size
and the availability of data from the real world setting, the
findings of this study are limited by a number of factors.
In contrast to national trends in antipsychotic prescribing
in England during the period 1998–2010 [41] and clinical
guidelines from the National Institute of Clinical Excel-
lence (NICE) [42] on prescribing for schizophrenia, con-
ventional antipsychotics were more commonly prescribed
as the initiating treatment in our study. These comparisons
suggest that the exposed population in this study may not
be representative of more current antipsychotic prescribing
practices in the community. We are nonetheless confident
that the exposed population was reflective of actual clinical
practice as our observations are supported by a previous
study undertaken in the GPRD [43]. King et al. reported
a similar distribution of antipsychotic prescribing shortly
after the introduction of atypical antipsychotics in the
UK and found that older patients with schizophrenia and
schizoaffective disorder were significantly less likely to be
prescribed atypical antipsychotics relative to conventional
antipsychotics. According to this study a five-year increase
in age was associated with a 15% decrease in the probability
of being prescribed an atypical antipsychotic. Given that
atypical antipsychotics were just being introduced during
the earlier parts of our study, that there were low periods
of uptake during the study period, that the average age of
our exposed population was about 60 years, and NICE rec-
ommendations on the prescribing of atypical antipsychotics
only became available during 2002/2003, we feel that the
distribution of prescribing observed in this study is plausible
and representative of antipsychotic prescribing during the
study period.
Due to the lack of information on important confound-
ing factors such as the underlying severity of psychiatric
disease or metabolic changes associated with antipsychotic
treatment, these factors could not be addressed in this study.
Psychiatric disease severity is also difficult to record; over
sixty percent of the exposed cohort did not have a clinical
or referral record for one of the four psychiatric diseases
considered. This may be partly explained by the fact that
more specific mental health diagnoses are likely to be made
in secondary care or in the community mental health setting
and that this information is not adequately communicated
back to the general practice. Another potential explanation
is the stigma associated mental health disease and the effect
of documenting this in the patient record. Another limitation
is that the exposure information was based on prescription
information rather than by actual use. In addition, selection
bias is also possible given that patients with ventricular
arrhythmias (or any other underlying know cardiac con-
dition) may lead to a higher rate of monitoring by ECGs
and higher probability that the physician may record this
outcome.
The definition of sudden cardiac death was restricted
by the limited clinical detail in the GPRD records and the
lack of precise timing of the sequence of events that lead
to an out of hospital death. Moreover, death certificate data
may not be a reliable means of identifying sudden cardiac
death. We applied different definitions of SCD as a sensitivity
analysis but the secondary and tertiary SCD definitions
may have been broad. In an effort to overcome known
limitations of identifying SCD through use of electronic
medical record codes, a free text search strategy was used.
However, this approach was still limited, as many cases
had very little free text. Most commonly, “sudden death” or
“died suddenly” was the only free text available. When more
information was available, it was often determined that the
patient did not experience SCD (e.g., deaths due to motor
vehicle accident, drug overdose). The limited amount of
information in many of the cases likely led to a high number
of false positives. Other research has experienced the same
challenges in defining SCD using electronic medical records
[44].
In relation to the causes of SCD, it has long been
established that antiarrhythmic drugs are capable of pre-
cipitating ventricular tachyarrhythmias and sudden cardiac
death [45, 46]. It is therefore plausible that coprescription of
antidepressants [47–50], anti-infective agents [51], or other
arrhythmogenic drugs such as antihistamines [52, 53] may
explain the rates of all-cause mortality and SCD observed in
this study.The contribution of these factors to the risk of SCD
was not explored in this study.
Due to the dynamic nature of the GPRD, information
relating to important factors such as the date of onset and
diagnosis of psychiatric disorders are not always known or
accurately reported. This can have implications for ascer-
taining disease duration and severity. In our analysis of the
psychiatric non-user population, the reported duration of
psychiatric disease is underestimated given what is known
about the age of onset of psychiatric disorders—onset can
occur in adolescence for conditions such as schizophrenia or
arise in late adulthood for conditions such as dementia. Lack
of information to correctly classify disease duration could
potentially result in a heterogeneous comparison group; one
with varying propensities to be prescribed antipsychotic
therapies, differing clinical characteristics and risk factors for
death. The inability to adjust for confounding of this nature
in the database setting means that estimates of the risk of all-
cause and cardiac mortality among the psychiatric non-user
population should be regarded with caution.
Though several limitations are acknowledged, we believe
our findings contribute to the understanding of the potential
cardiac-related risks with antipsychotic exposure in patients
with severe mental illnesses.
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5. Conclusions
Current users of antipsychotics had an increased risk of
all-cause mortality, cardiac mortality, and risk of sudden
cardiac death when compared to both the general population
controls and the psychiatric nonuser cohort. However, the
risk of developing CHD and ventricular arrhythmias did not
differ significantly from the psychiatric nonusers. Psychiatric
nonusers with a diagnosis of bipolar disorder, schizophrenia,
and dementia had an increased risk of all-cause mortality
relative to the general population. Rates of all-cause mor-
tality, cardiac mortality, SCD (using the tertiary definition),
and CHD were significantly lower among users of atypical
antipsychotics compared to typical antipsychotic users. Both
all-cause mortality and cardiac mortality were higher among
antipsychotic users versus psychiatric nonusers. There is no
clear driver to explain this association. An increased risk of
all-cause mortality was seen in nonantipsychotic users with
schizophrenia, dementia, or bipolar disorder compared with
general population controls.
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